Generic clozapine: a cost-saving alternative to brand name clozapine?

Abstract:

:As a consequence of its prevalence, early onset and chronicity, schizophrenia imposes clinical and economic impediments to healthcare practitioners and society alike. Among the many antipsychotics available to treat the symptoms of this devastating illness, clozapine has emerged and differentiated itself from the others as the agent most efficacious for the treatment of refractory patients. Since the patent for Clozaril (Novartis) expired in 1998, three manufacturers of generic clozapine have submitted abbreviated new drug applications to the US FDA for review and approval to market a generic clozapine product. In each case, the US FDA deemed the generic formulations to be bioequivalent to the brand name Clozaril. Apart from case reports, industry-sponsored studies have been conducted comparing Clozaril with two generic formulations. In one case, a generic formulation of clozapine manufactured by Creighton Products Corporation (formerly a subsidiary [generic house] of Sandoz Pharmaceuticals) was found to be bioequivalent to Clozaril. On the other hand, studies (sponsored by Novartis) have challenged the bioequivalence, therapeutic equivalence and interchangeability between Clozaril and a generic formulation manufactured by Zenith Goldline Pharmaceuticals (now IVAX Corporation). The IVAX Corporation-sponsored studies refuted these claims citing data from two patient registry database studies and one small clinical trial. Apart from a single in-house bioequivalence study, no further investigations have been conducted with a third generic formulation manufactured by Mylan Pharmaceutical. Although the clinical significance of the above discrepancy is obvious, what is less than obvious is the pharmacoeconomic implications that arises from this debate. Clearly, if the brand name and generic formulations are 'truly' bioequivalent, then the cost savings realised would be the difference in acquisition cost. On the other hand, if the various formulations are not bioequivalent, then the economic benefits of a lower-priced generic formulation may be compromised. In the worst-case scenario, if a patient decompensates as a result of switching from Clozaril to a generic formulation, the added direct costs (i.e. hospitalisation) and indirect cost (i.e. lost productivity) will most certainly offset any cost savings resulting from the use of a generic formulation. Until further studies have been conducted, we suggest that patients who are treatment refractory and stabilised on Clozaril are not switched to a generic formulation. On the other hand, if a patient is stabilised on Clozaril and not treatment refractory, then cautious switching to a generic formulation may be reasonable. Finally, initiating a generic formulation in a 'clozapine-naïve' individual would be appropriate. The cost implications related to these recommendations will depend on the success or failure of treatment.

journal_name

Pharmacoeconomics

journal_title

PharmacoEconomics

authors

Tse G,Thompson D,Procyshyn RM

doi

10.2165/00019053-200321010-00001

subject

Has Abstract

pub_date

2003-01-01 00:00:00

pages

1-11

issue

1

eissn

1170-7690

issn

1179-2027

pii

210101

journal_volume

21

pub_type

杂志文章,评审
  • Formulary management of ACE inhibitors.

    abstract::An increasing number of ACE inhibitors have become available in recent years. Because these agents are all similar, careful scrutiny is required in order to determine specific advantages of particular agents when making formulary decisions. Differences between agents with regard to structure and tissue specificity hav...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-199610060-00006

    authors: Gerbrandt KR,Yedinak KC

    更新日期:1996-12-01 00:00:00

  • Cost-minimisation analysis of sequential treatment with ofloxacin or ciprofloxacin in hospitalised patients.

    abstract::This study evaluated the cost of sequential treatment with once-daily ofloxacin or twice-daily ciprofloxacin in 474 hospitalised patients in different countries. The patients were treated intravenously for at least 3 days, then orally for 7 to 10 days or for 3 days beyond the disappearance of infection-related symptom...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199711040-00007

    authors: Salewski E,Bassaris HP,Calangu S,Kitzes R,Kosmidis J,Raz R,Kompan L

    更新日期:1997-04-01 00:00:00

  • Economic value of thrombolysis with adjunctive abciximab in patients with subacute peripheral arterial occlusion.

    abstract:BACKGROUND AND OBJECTIVE:Glycoprotein (GP) IIb/IIIa receptor inhibitors enhance thrombolysis in patients with acute coronary syndromes. This analysis evaluates the economic impact of abciximab, a GP IIb/IIIa inhibitor, as an adjunct to urokinase in peripheral artery occlusions of less than 6 weeks duration. STUDY DESI...

    journal_title:PharmacoEconomics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00019053-200220030-00006

    authors: Duda SH,Tepe G,Bala M,Luz O,Ziemer G,Ouriel K,Pusich B,Wiskirchen J,Claussen CD,Banz K

    更新日期:2002-01-01 00:00:00

  • The role of pharmacoepidemiology and pharmacoeconomics in promoting access and stimulating innovation.

    abstract::Answering the demanding questions asked of pharmacotherapy in the 21st century will require more reliance on the disciplines of pharmacoepidemiology and pharmacoeconomics. Pharmacoepidemiology can help assess patterns and appropriateness of drug utilisation, provide explanations for poor compliance, quantify the frequ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-200422002-00009

    authors: Avorn J

    更新日期:2004-01-01 00:00:00

  • Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.

    abstract::Patients with schizophrenia suffer numerous relapses and rehospitalizations that are associated with high direct and indirect medical expense. Suboptimal therapeutic efficacy and, in particular, problems with compliance are major factors leading to relapse. Atypical antipsychotic agents offer improved efficacy and a l...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200523001-00004

    authors: De Graeve D,Smet A,Mehnert A,Caleo S,Miadi-Fargier H,Mosqueda GJ,Lecompte D,Peuskens J

    更新日期:2005-01-01 00:00:00

  • Costs of irritable bowel syndrome in the UK and US.

    abstract::Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders, with an estimated prevalence rate in the general population of 10-15% in industrialised countries. Although IBS is not a life-threatening disease, it contributes significantly to a large segment of healthcare resource consu...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-200624010-00002

    authors: Maxion-Bergemann S,Thielecke F,Abel F,Bergemann R

    更新日期:2006-01-01 00:00:00

  • Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer.

    abstract:BACKGROUND:The recently completed ALEX trial demonstrated that alectinib improved progression-free survival, and delayed time to central nervous system progression compared with crizotinib in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer. However, the long-term clinical and economic impac...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-018-0625-6

    authors: Carlson JJ,Suh K,Orfanos P,Wong W

    更新日期:2018-04-01 00:00:00

  • The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments.

    abstract:OBJECTIVE:The aim of this review is to provide a summary of the literature on risk-sharing agreements, including conceptual, theoretical and empirical (number of agreements and their achievements) perspectives, and stakeholders'  perceptions. METHODS:We conducted a systematic literature search in MEDLINE from 2000 to ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-019-00838-w

    authors: Antonanzas F,Juárez-Castelló C,Lorente R,Rodríguez-Ibeas R

    更新日期:2019-12-01 00:00:00

  • Healthcare reform and expenditure on drugs. The German situation.

    abstract::Germany is in a period of transition with regard to healthcare reform. The number and intensity of cost control interventions increased during the last decade in an attempt to contain healthcare expenditure. The German legislature has implemented long term macroeconomic measures such as contribution rate stability and...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199600102-00013

    authors: Ulrich V,Wille E

    更新日期:1996-01-01 00:00:00

  • Cost evaluation of basiliximab treatment for renal transplant patients in Japan.

    abstract:BACKGROUND:International phase III studies (CHIB 201 and 352) showed that basiliximab, a high affinity chimeric monoclonal antibody interleukin-2 receptor antagonist, is highly effective in preventing acute rejection when used as immunoprophylaxis in patients receiving cyclosporin (Neoral). We conducted a cost evaluati...

    journal_title:PharmacoEconomics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00019053-200321110-00003

    authors: Hasegawa T,Imai H,Miki S

    更新日期:2003-01-01 00:00:00

  • Time trends and determinants of pharmaceutical expenditure in China (1990-2009).

    abstract:BACKGROUND:Pharmaceutical policy reform is currently one of the primary areas of health reform in China. The national pharmaceutical policy of China has multiple objectives: to develop the domestic pharmaceutical industry and encourage innovation, to control escalation of total pharmaceutical expenditures (TPE) which c...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-013-0072-3

    authors: Shi L,Yang HY,Cheng G,Meng Q

    更新日期:2014-03-01 00:00:00

  • Cost-effectiveness analysis of topical calcipotriol versus short-contact dithranol. In the treatment of mild to moderate plaque psoriasis.

    abstract:OBJECTIVE:To examine the relative cost effectiveness of topical calcipotriol and short-contact dithranol in the treatment of mild to moderate plaque psoriasis. DESIGN AND SETTING:This was a modelling study from the perspective of the UK National Health Service as payer. METHODS:The interventions were compared using 2...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200018050-00006

    authors: Ashcroft DM,Li Wan Po A,Williams HC,Griffiths CE

    更新日期:2000-11-01 00:00:00

  • Economic and developmental considerations for pharmacogenomic technology.

    abstract::The pharmaceutical industry's core business is the innovation, development and marketing of new drugs. Pharmacogenetic (PG) testing and technology has the potential to increase a drug's value in many ways. A critical issue for the industry is whether products in development should be teamed with genetic tests that cou...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200624040-00004

    authors: Vernon JA,Johnson SJ,Hughen WK,Trujillo A

    更新日期:2006-01-01 00:00:00

  • Statistical versus quantitative significance in the socioeconomic evaluation of medicines.

    abstract::This article examines the twin concepts of the statistical significance and quantitative importance of observed differences in studies comparing medicines in terms of economic parameters such as cost-effectiveness and measures of health-related quality of life (HRQOL). Central to the design and interpretation of any ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-199405050-00005

    authors: O'Brien BJ,Drummond MF

    更新日期:1994-05-01 00:00:00

  • The cost of inadequate prescriptions for hypolipidaemic drugs. VICAF Group.

    abstract:BACKGROUND:The high consumption of hypolipidaemic agents warrants the study of the costs caused by these medicines being inadequately prescribed. OBJECTIVE:To quantify the economic cost generated in 1 year in primary care by inadequate (or unnecessary) prescriptions for hypolipidaemic drugs. METHODS:A cross-sectional...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200119050-00006

    authors: Ballesteros LC,Fernández San Martín MI,Sanz Cuesta T,Escortell Mayor E,López Bilbao C

    更新日期:2001-01-01 00:00:00

  • The humanistic burden of head and neck cancer: a systematic literature review.

    abstract:BACKGROUND:Head and neck cancer (HNC) and its treatment can affect communication, nutrition, and physical appearance, and the global impact of this disease on patients' quality of life may be substantial. OBJECTIVE:The aim of this systematic literature review was to describe the impact of HNC and its treatment on the ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.1007/s40273-014-0199-x

    authors: Wissinger E,Griebsch I,Lungershausen J,Byrnes M,Travers K,Pashos CL

    更新日期:2014-12-01 00:00:00

  • Does a Patient-Directed Financial Incentive Affect Patient Choices About Controller Medicines for Asthma? A Discrete Choice Experiment and Financial Impact Analysis.

    abstract:BACKGROUND:In Australia, many patients who are initiated on asthma controller inhalers receive combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) despite having asthma of sufficiently low severity that ICS-alone would be equally effective and less costly for the government. METHODS:We conducted a ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-018-0731-5

    authors: Laba TL,Reddel HK,Zwar NJ,Marks GB,Roughead E,Flynn A,Goldman M,Heaney A,Lembke K,Jan S

    更新日期:2019-02-01 00:00:00

  • Correction to: Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-alcoholic Fatty Liver Disease in Thailand.

    abstract::Weight Reduction is Cost-Effective for the Treatment of Non-alcoholic Fatty Liver Disease in Thailand. ...

    journal_title:PharmacoEconomics

    pub_type: 已发布勘误

    doi:10.1007/s40273-018-0754-y

    authors: Chongmelaxme B,Phisalprapa P,Manthaisong R,Dilokthornsakul P,Chaiyakunapruk N

    更新日期:2019-02-01 00:00:00

  • Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal.

    abstract::The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of golimumab (Schering-Plough/Centocor) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of active and progressive psoriatic arthritis (PsA) in patients who have responded inadequately to ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/11595920-000000000-00000

    authors: Yang H,Craig D,Epstein D,Bojke L,Light K,Bruce IN,Sculpher M,Woolacott N

    更新日期:2012-04-01 00:00:00

  • Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.

    abstract:OBJECTIVE:The objective of this study was to evaluate the cost effectiveness of no prophylaxis, primary prophylaxis (PP), or secondary prophylaxis (SP) with granulocyte colony-stimulating factors (G-CSFs), i.e., pegfilgrastim, lipegfilgrastim, filgrastim (6- and 11-day), or lenograstim (6- and 11-day), to reduce the in...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-016-0474-0

    authors: Fust K,Li X,Maschio M,Villa G,Parthan A,Barron R,Weinstein MC,Somers L,Hoefkens C,Lyman GH

    更新日期:2017-04-01 00:00:00

  • Formulary management of antiulcer drugs: economic considerations.

    abstract::Peptic ulcer disease (PUD) is a common medical problem costing billions of dollars annually around the world. Since the availability of the first histamine H2-receptor antagonist, cimetidine, many economic analyses have been conducted to compare the impact of this drug class on resource consumption. H2-Antagonists h...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-199405040-00006

    authors: Tucker PP,Nash DB

    更新日期:1994-04-01 00:00:00

  • Alcoholism. The cost of illness in the Federal Republic of Germany.

    abstract::The purpose of this study was to estimate the direct and indirect costs of alcoholism in the Federal Republic of Germany. Direct costs comprised treatment costs, while indirect costs consisted mainly of costs incurred as a result of work time lost, as well as costs related to premature retirement and premature mortali...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199610050-00006

    authors: Brecht JG,Poldrugo F,Schädlich PK

    更新日期:1996-11-01 00:00:00

  • A model to compute the medical cost of patients in intensive care.

    abstract:OBJECTIVE:Our objective was to identify, among the information routinely collected on patients in intensive care units (ICUs), data that determine the total cost for a given patient. DESIGN:We developed a model that could help physicians in medical ICUs to estimate the cost of care for their patients when no cost data...

    journal_title:PharmacoEconomics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00019053-199915060-00005

    authors: Chaix C,Durand-Zaleski I,Alberti C,Brun-Buisson C

    更新日期:1999-06-01 00:00:00

  • Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER.

    abstract:BACKGROUND:Given the association between CD4 cell counts and HIV-related morbidity/mortality, new antiretroviral therapies could potentially lower the direct costs of HIV care by raising CD4 cell counts. OBJECTIVES:To predict the effects of the ritonavir-boosted, HIV protease inhibitor (PI) darunavir on the direct cos...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/11587510-000000000-00000

    authors: Hill AM,Gebo K,Hemmett L,Löthgren M,Allegri G,Smets E

    更新日期:2010-01-01 00:00:00

  • A systematic review to assess the policy-making relevance of dementia cost-of-illness studies in the US and Canada.

    abstract::A systematic review of dementia cost-of-illness (COI) studies in the US and Canada was conducted to explore the policy-making relevance of these studies. MEDLINE, CINAHL, EconLit, AMED and the Cochrane Library were searched from inception to March 2010 for English-language COI articles. Content analysis was used to ex...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/11539450-000000000-00000

    authors: Oremus M,Aguilar SC

    更新日期:2011-02-01 00:00:00

  • Enoxaparin: a pharmacoeconomic review of its use in the prevention and treatment of venous thromboembolism and in acute coronary syndromes.

    abstract::The pharmacoeconomics of the low molecular weight heparin (LMWH) enoxaparin in the prophylaxis and treatment of venous thromboembolism have mostly been investigated in cost-effectiveness studies that estimated direct costs associated with treatment, using decision analyses and clinical outcome data from randomised con...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200220040-00002

    authors: Bergqvist D

    更新日期:2002-01-01 00:00:00

  • Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology Assessment.

    abstract::There is growing interest in using observational data to assess the safety, effectiveness, and cost effectiveness of medical technologies, but operational, technical, and methodological challenges limit its more widespread use. Common data models and federated data networks offer a potential solution to many of these ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-020-00981-9

    authors: Kent S,Burn E,Dawoud D,Jonsson P,Østby JT,Hughes N,Rijnbeek P,Bouvy JC

    更新日期:2020-12-18 00:00:00

  • The future of health technology assessment in healthcare decision making in Asia.

    abstract::Most countries have healthcare resource constraints and it is easy to identify new health technologies as an area in need of resource management, particularly given that new health technologies usually increase rather than save costs. Resource constraints are even more noticeable in Asia than in other regions, with a ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/11310280-000000000-00000

    authors: Yang BM

    更新日期:2009-01-01 00:00:00

  • A multinational investigation of the impact of subcutaneous sumatriptan. II: Health-related quality of life.

    abstract::The aim of this prospective sequential multinational (5 countries) study was to concurrently evaluate the effects of subcutaneous sumatriptan on clinical parameters, health-related quality-of-life (HRQOL) measures, workplace productivity and patient satisfaction. This report presents the HRQOL results. 582 patients (a...

    journal_title:PharmacoEconomics

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.2165/00019053-199700111-00005

    authors: Dahlöf C,Bouchard J,Cortelli P,Heywood J,Jansen JP,Pham S,Hirsch J,Adams J,Miller DW

    更新日期:1997-01-01 00:00:00

  • The applicability and generalizability of findings from clinical trials for health-policy decisions.

    abstract::Randomized controlled trials provide unbiased estimates of treatment effect through reducing the attribution of observed differences in outcome to the play of chance or the treatment of interest. Issues in the design of randomized trials may lead to a dilution or magnification of treatment effect when compared with cl...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200927010-00002

    authors: Freemantle N,Hessel F

    更新日期:2009-01-01 00:00:00